Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liothyronine for cognitive protection during electroconvulsive therapy in mood disorders
IRCT20150427021965N11Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of liothyronine in affective disorder, bipolar disorder (BD) and major depressive disorder (MDD) (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Cognitive status of patients. Started Aug 2019; status: completed.
02
Drugs
liothyronine
03
Conditions
affective disorderbipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20150427021965N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150427021965N11.